PFS is improved with use of a TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy, although OS is not statistically different. Please summarize clinical results.

PFS is improved with use of a TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy, although OS is not statistically different. Please summarize clinical results.

PFS is improved with use of a TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy, although overall survival is not statistically different? Please summarize clinical results.


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Paul Mitchell, BHB, MBChB, FRACP, MD

Paul Mitchell, BHB, MBChB, FRACP, MD

Associate Professor
Senior Specialist
Austin Health Cancer Services
Director, North Eastern Metropolitan Integrated Cancer Services (NEMICS)
Melbourne, Australia